Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients have?
Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients has 190 citations in the OpenAlex counts ScholarIQ stores.
When was Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients published?
Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients has 2016 year in the ScholarIQ index.
What is the open-access status of Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients?
Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients has bronze oa status in the ScholarIQ index.
What is the DOI of Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients?
The DOI for Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients is on the source record.
What is the PMID of Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients?
The PMID for Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients is on the source record.
What is the OpenAlex record for Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients?
The OpenAlex for Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients is on the source record.